Liberate Bio
Boston
About Liberate Bio
Liberate Bio focuses on advancing non-viral delivery technologies for nucleic acid cargoes such as ASOs and siRNAs. The company aims to develop new vehicles to deliver oligonucleotide cargos, addressing genetic disorders. With a team of 50 employees, Liberate Bio operates within the biotechnology industry, working on innovative solutions for targeted delivery systems.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $31.0M
- Funding stage: Seed
- Last round: Seed (Oct 2025)
- Website: liberatebio.com
- Phone: [email protected]
Industries & Categories
Bioinformatics, Biotechnology, Genetics
Social Profiles
Canonical: https://fsome.com/organization/liberate-bio-25606 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.